The pharmaceutical industry has always been important to the national economy and people's livelihood. It is a key area of strategic emerging industries and an important guarantee for the Health China Strategy. Patent is an important indicator of technological innovation and an important system for the protection of pharmaceutical intellectual property rights. In order to figure out the relationship between pharmaceutical technology innovation and patent protection, in response to the "Implementation Measures for the Early Resolution Mechanism for Drug Patent Disputes " issued by the National Medical Product Administration and the National Intellectual Property Administration on September 11, 2020, The Pharmaceutical Law and Intellectual Property Research Center of Shanghai International College of Intellectual Property of Tongji University, cooperate with the Pharmaceutical Intellectual Property Committee of the China Health Law Society, the Pharmaceutical Intellectual Property Committee of the Chinese Pharmaceutical Association, and the IP Economy Magazine to hold the symposium, more than 50 guests from Shenyang Pharmaceutical University, China Pharmaceutical University, Tongji University, East China University of Political Science and Law, Zhejiang University of Traditional Chinese Medicine, Patent Examination Cooperation Jiangsu Center of the National Intellectual Property Administration, Shanghai Intellectual Property Court, WuXi Biologics Co., Ltd., Sansheng Guojian Pharmaceutical (Shanghai) Co., Ltd., Luye Pharmaceutical Group, Chengdu Kanghong Pharmaceutical Group Co., Ltd., Shijiazhuang Pharmaceutical Group Co., Ltd. (CSPC), Zhejiang Conba Pharmaceutical Co., Ltd., Guangzhou Pharmaceutical Holdings Limited (GPHL), Nanjing Sanhome Pharmaceutical Co., Ltd., Beijing Intellectual Property Institute, "Technology • IP Economy", Shanghai David Levin Intellectual Property Agency Co., Ltd., Beijing King&Capital Law Firm and other representatives attended the meeting online.

Prof. Song Xiaoting, the head of the Pharmaceutical Intellectual Property Committee of the Chinese Health Law Society, and Prof. Ding Jinxi, the Deputy head of the Pharmaceutical Intellectual Property Committee of the Chinese Pharmaceutical Association, respectively delivered speeches at the opening ceremony. They introduced the background and prospects of the issue and said they would strengthen the two Committees’ cooperation on professional pharmaceutical issues.

The symposium made deep discussions and research on related legal and intellectual property issues such as the necessity and purpose of establishing patent linkage system in China, the solution to patent disputes before the releasing of generic drugs, the basic framework and mechanism construction of the operation of the Chinese patent linkage system. Guests believed that the introduction of the “Implementation Measures for the Early Resolution Mechanism for Drug Patent Disputes” is necessary, but it also involves the cooperation between the drug administrative department, the intellectual property administrative department and the court.

The Pharmaceutical Law and Intellectual Property Research Center of Shanghai International College of Intellectual Property was established in 2010. It promotes the development of pharmaceutical intellectual property and serves the country, society by combining with medicine, life sciences, chemistry and other related disciplines. The research areas of the center include legal and intellectual property policy issues in the field of biomedicine, public health, innovation and intellectual property issues, traditional medicine and traditional legal protection issues, and legal issues in the development of pharmaceutical technology.